Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed enrollment in its global Phase 3 YOSEMITE clinical trial of zodasiran, an investigational RNA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE